Combining PRMT5 inhibitors with DNA-damaging chemotherapies and/or innovative DDR inhibitors targeting could widen the therapeutic window that promotes effective BCSC and bulk tumour cell eradication whilst minimising unwanted toxicities. This evidence concerns the gene PRMT5 and neoplasm.